Apparently, the down regulation of PI3K-AKT-mTOR signaling is also crucial for the recovery following cisplatin administration and for improving cisplatin sensitivity in hepatocellular carcinoma [62], lung cancer [63,64], gastric cancer [65,66], and cervical cancer [67]. The gene discussed is MTOR; the disease is lung cancer.